Chapter 2 - The Patent With My Name on It
The next morning, Tristan made coffee.
That may sound insignificant.
It wasn't.
For seven years, I had made his.
Black, one teaspoon of honey, no milk.
That morning he placed a mug beside my laptop and kissed the top of my head as if he had not driven another woman home twelve hours earlier.
“Tessa was pretty embarrassed about last night.”
I kept reading an email.
“Was she?”
“People were being stupid.”
“Which people?”
He hesitated.
“The kiss thing.”
I looked up.
“You mean people daring a man to kiss his fiancée thirty days before their wedding?”
His expression tightened.
There.
The smallest flash of irritation.
“You know what I mean.”
I did.
That was the problem.
Tristan had spent years training me to translate his discomfort into my responsibility.
I closed the laptop.
“Long day?”
“Investor meetings.”
“What investors?”
His eyes sharpened.
“You've never cared about financing details.”
That sentence almost made me smile.
I had written the scientific assumptions underneath every financing deck Asterion Therapeutics had ever used.
But Tristan had spent so many years describing himself as the founder and CEO that eventually he began treating me like the scientist he happened to marry rather than the woman who had made the company possible.
“Right,” I said.
His shoulders relaxed.
He kissed me again.
Then left.
At 8:40, I called Lena Walsh.
Lena had been my attorney since graduate school.
Not Asterion's attorney.
Mine.
That distinction suddenly mattered.
She met me in her office before lunch.
I showed her the screenshots.
She looked at them once.
Then slid the pages back.
“Do you want relationship advice or legal advice?”
“Legal.”
“Good. I'm terrible at the first.”
Despite myself, I laughed.
Then I told her what worried me more than the affair.
The company.
Asterion Therapeutics had begun seven years earlier with three people, two borrowed laboratory benches, and an assay platform I had built during my postdoctoral work.
The Hastings Molecular Response Engine.
HMRE.
Terrible name.
Good science.
The platform could identify patterns in patient-derived cellular responses faster than the standard screening approaches we had used before.
It did not cure cancer.
It did not predict miracles.
It simply produced useful biological information efficiently enough that pharmaceutical companies wanted access.
Tristan knew how to turn scientific potential into a company.
I knew how to make the science work.
That partnership had once been real.
The important part was ownership.
Before Asterion existed, I had assigned my early patents to Hastings BioSystems LLC.
My company.
Asterion received an exclusive license.
Not ownership.
Tristan knew.
He had signed the original license agreement himself.
But over the years, Asterion's investor materials became increasingly vague.
Our technology.
Our proprietary engine.
Our platform.
Then:
Asterion's patented platform.
I had complained twice.
Tristan called the wording harmless.
“Investors don't care about legal grammar,” he told me.
Lena cared.
“Bring me the current license.”
I did.
She read the termination provisions.
If Asterion materially misrepresented ownership, transferred rights without approval, or used the patents outside approved fields, Hastings BioSystems could demand cure and potentially suspend portions of the license.
“I don't want to destroy the company.”
“Good.”
“Fifty-four people work there.”
“Also good.”
“I don't want revenge.”
“Even better.”
She closed the document.
“What do you want?”
“The truth.”
That sounded simple.
It wasn't.
Lena recommended we preserve records before Tristan knew I had questions.
Board decks.
Cap tables.
Licensing agreements.
Investor presentations.
Patent correspondence.
I had rights as co-founder, chief scientific officer, director, and significant shareholder.
At 2:17 that afternoon, I opened the most recent investor deck.
Slide two:
ASTERION THERAPEUTICS
Founder and CEO: Tristan Davis.
No co-founder.
No Dr. Zoe Hastings.
I kept reading.
Slide six described HMRE as “Asterion's wholly controlled proprietary technology platform.”
Wholly controlled.
False.
Slide eleven described our newest oncology partnership.
Slide sixteen described a future licensing expansion into neurological disease.
I stopped.
Neurology was not covered by Asterion's current exclusive license.
I had specifically withheld that field.
Tristan knew.
I searched the shared drive.
Nothing.
Then I found a folder with permissions accidentally inherited from the executive group.
PROJECT NORTHLIGHT.
Inside was a draft agreement.
Asterion Therapeutics would sublicense HMRE neurological applications to another company.
Northlight Biomedical.
I had never approved it.
Then I saw Northlight's ownership table.
Tristan Davis: 41 percent.
Three outside investors.
And Tessa Monroe: 8 percent.
My hands went cold.
The affair suddenly became the least interesting document in the room.
Northlight planned to license technology Tristan did not own.
Technology Asterion itself could not legally transfer without me.
Then came a draft board consent.
Approved unanimously.
Director: Tristan Davis.
Director: Miriam Chen.
Director: Zoe Hastings.
My signature appeared beneath.
Except I had never seen it.
I stared at the image.
It looked like mine.
Very good.
Wrong.
At 3:06, I called Lena.
“It's bigger.”
“How much bigger?”
“Someone signed my name.”
She stopped speaking.
Then:
“Do not confront him.”
“I know.”
“Zoe.”
“I know.”
But I did not know the worst part yet.
At 4:12, our finance director emailed the executive team a reminder.
Northlight financing materials were going to investors Friday.
The wedding was twenty-nine days away.
May you like
Tristan was not simply cheating before marrying me.
He was preparing to use the wedding as proof of stability while moving my scientific platform into a company where his mistress owned eight percent.
Related Stories
